Swedencare AB (publ)

OTCPK:SWDC.F Stock Report

Market Cap: US$679.4m

Swedencare Past Earnings Performance

Past criteria checks 2/6

Swedencare has been growing earnings at an average annual rate of 20.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 49.6% per year. Swedencare's return on equity is 0.8%, and it has net margins of 2.5%.

Key information

20.3%

Earnings growth rate

5.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate49.6%
Return on equity0.8%
Net Margin2.5%
Next Earnings Update13 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Swedencare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:SWDC.F Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,504628980
30 Jun 242,472768590
31 Mar 242,414728300
31 Dec 232,338598030
30 Sep 232,208877500
30 Jun 232,085537260
31 Mar 231,987976900
31 Dec 221,843956400
30 Sep 221,600985470
30 Jun 221,3351054560
31 Mar 221,019603450
31 Dec 21773552590
30 Sep 21618402050
30 Jun 21465441460
31 Mar 21337341140
31 Dec 2024033870
30 Sep 2017434720
30 Jun 2013628610
31 Mar 2013430580
31 Dec 1912730540
30 Sep 1912130500
30 Jun 1911328480
31 Mar 1910827470
31 Dec 189923440
30 Sep 189423410
30 Jun 189220420
31 Mar 188517410
31 Dec 178617400
30 Sep 177812390
30 Jun 177011350
31 Mar 176312310
31 Dec 165410280
30 Sep 16439230
30 Jun 16378190
31 Mar 16348150
31 Dec 15277100
31 Dec 1424490
31 Dec 1318090

Quality Earnings: SWDC.F has high quality earnings.

Growing Profit Margin: SWDC.F's current net profit margins (2.5%) are lower than last year (4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SWDC.F's earnings have grown significantly by 20.3% per year over the past 5 years.

Accelerating Growth: SWDC.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SWDC.F had negative earnings growth (-28.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).


Return on Equity

High ROE: SWDC.F's Return on Equity (0.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 23:49
End of Day Share Price 2024/11/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Swedencare AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Johan BrownABG Sundal Collier Sponsored
Martin ComtesseJefferies LLC
Adrian ElmlundNordea Markets